On Biostatistics and Clinical Trials
CQ's web blog on the issues in biostatistics and clinical trials.
Thursday, December 22, 2016
Control for Type I Error (or Adjustment for Multiplicity) for Secondary Endpoints
›
In clinical trial protocols, we usually specify one or more primary efficacy endpoints, then a list of secondary efficacy endpoints, and th...
4 comments:
Tuesday, December 20, 2016
the 21st Century Cures Act and Innovations in Clinical Trials
›
After the bill passed through house and senator, the president Obama signed the bill into law on December 13, 2016. The 21st Century Cures A...
Sunday, December 11, 2016
Commonly Used Procedure for Multiplicity Adjustment: Fixed Sequence Procedure, Holm Step-down Procedure, Hochberg Step-up Procedure
›
In clinical trials, we often have the multiple tests or multiplicity issue when there are more than one hypothesis tests built in the same ...
Thursday, November 24, 2016
Should the Percent of Confidence Confidence Interval Match the Significance Level?
›
In statistics, a confidence interval (CI) is a type of interval estimate of a population parameter. Confidence intervals consist of a r...
1 comment:
Monday, November 21, 2016
Haybittle–Peto Boundary for Stopping the Trial for Efficacy or Futility at Interim Analysis
›
In clinical trials with group sequential design or the clinical trials with formal interim analysis for efficacy, we will need to deal with...
‹
›
Home
View web version
